Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Emanuela Tassoni

Maria Ornella Tinti

Fabio Giannessi

Pompeo Pessotto

Walter Cabri

Mauro Marzi

Maurizio Botta

Fabrizio Giorgi

Natalina Dell'Uomo

Tiziana Brunetti

Anna Floriana Sciarroni

Ferdinando Maria Milazzo

Pederico Corelli

Monica Bandera

The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.

Crystalline teglicar

The use is described of derivatives of &#x3b1;-phenylthiocarboxylic and &#x3b1;-phenyloxycarboxylic acids with formula (i): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias 

Use of &#x3b1;-phenylthiocarboxylic and &#x3b1;-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity

Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. They are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms of insulin resistance, and hyperlipidaemias, as well as for the treatment of obesity.

Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity

Growing community of inventors

Pomezia, Italy

Emanuela Tassoni